243 related articles for article (PubMed ID: 15078145)
1. Discovery and development of GSK3 inhibitors for the treatment of type 2 diabetes.
Wagman AS; Johnson KW; Bussiere DE
Curr Pharm Des; 2004; 10(10):1105-37. PubMed ID: 15078145
[TBL] [Abstract][Full Text] [Related]
2. Glycogen synthase kinase 3: more than a namesake.
Rayasam GV; Tulasi VK; Sodhi R; Davis JA; Ray A
Br J Pharmacol; 2009 Mar; 156(6):885-98. PubMed ID: 19366350
[TBL] [Abstract][Full Text] [Related]
3. Inhibitors of Glycogen Synthase Kinase 3 with Exquisite Kinome-Wide Selectivity and Their Functional Effects.
Wagner FF; Bishop JA; Gale JP; Shi X; Walk M; Ketterman J; Patnaik D; Barker D; Walpita D; Campbell AJ; Nguyen S; Lewis M; Ross L; Weïwer M; An WF; Germain AR; Nag PP; Metkar S; Kaya T; Dandapani S; Olson DE; Barbe AL; Lazzaro F; Sacher JR; Cheah JH; Fei D; Perez J; Munoz B; Palmer M; Stegmaier K; Schreiber SL; Scolnick E; Zhang YL; Haggarty SJ; Holson EB; Pan JQ
ACS Chem Biol; 2016 Jul; 11(7):1952-63. PubMed ID: 27128528
[TBL] [Abstract][Full Text] [Related]
4. Acute selective glycogen synthase kinase-3 inhibition enhances insulin signaling in prediabetic insulin-resistant rat skeletal muscle.
Dokken BB; Sloniger JA; Henriksen EJ
Am J Physiol Endocrinol Metab; 2005 Jun; 288(6):E1188-94. PubMed ID: 15671078
[TBL] [Abstract][Full Text] [Related]
5. The glamour and gloom of glycogen synthase kinase-3.
Jope RS; Johnson GV
Trends Biochem Sci; 2004 Feb; 29(2):95-102. PubMed ID: 15102436
[TBL] [Abstract][Full Text] [Related]
6. GSK3: a key target for the development of novel treatments for type 2 diabetes mellitus and Alzheimer disease.
Gao C; Hölscher C; Liu Y; Li L
Rev Neurosci; 2011 Dec; 23(1):1-11. PubMed ID: 22718609
[TBL] [Abstract][Full Text] [Related]
7. GSK3 takes centre stage more than 20 years after its discovery.
Frame S; Cohen P
Biochem J; 2001 Oct; 359(Pt 1):1-16. PubMed ID: 11563964
[TBL] [Abstract][Full Text] [Related]
8. GSK3 Inhibitors in the Therapeutic Development of Diabetes, Cancer and Neurodegeneration: Past, Present and Future.
Maqbool M; Hoda N
Curr Pharm Des; 2017 Nov; 23(29):4332-4350. PubMed ID: 28714403
[TBL] [Abstract][Full Text] [Related]
9. Metabolism and insulin signaling in common metabolic disorders and inherited insulin resistance.
Højlund K
Dan Med J; 2014 Jul; 61(7):B4890. PubMed ID: 25123125
[TBL] [Abstract][Full Text] [Related]
10. Glycogen Synthase Kinase 3 (GSK3): Its Role and Inhibitors.
Wadhwa P; Jain P; Jadhav HR
Curr Top Med Chem; 2020; 20(17):1522-1534. PubMed ID: 32416693
[TBL] [Abstract][Full Text] [Related]
11. Use of lithium and SB-415286 to explore the role of glycogen synthase kinase-3 in the regulation of glucose transport and glycogen synthase.
MacAulay K; Hajduch E; Blair AS; Coghlan MP; Smith SA; Hundal HS
Eur J Biochem; 2003 Sep; 270(18):3829-38. PubMed ID: 12950267
[TBL] [Abstract][Full Text] [Related]
12. Challenges and opportunities with glycogen synthase kinase-3 inhibitors for insulin resistance and Type 2 diabetes treatment.
Eldar-Finkelman H; Ilouz R
Expert Opin Investig Drugs; 2003 Sep; 12(9):1511-9. PubMed ID: 12943495
[TBL] [Abstract][Full Text] [Related]
13. Recent advances in the discovery of 11beta-HSD1 inhibitors.
Boyle CD
Curr Opin Drug Discov Devel; 2008 Jul; 11(4):495-511. PubMed ID: 18600567
[TBL] [Abstract][Full Text] [Related]
14. Characterization and development of novel small-molecules inhibiting GSK3 and activating Wnt signaling.
Zhong H; Zou H; Semenov MV; Moshinsky D; He X; Huang H; Li S; Quan J; Yang Z; Lin S
Mol Biosyst; 2009 Nov; 5(11):1356-60. PubMed ID: 19823752
[TBL] [Abstract][Full Text] [Related]
15. Substituted 3-imidazo[1,2-a]pyridin-3-yl- 4-(1,2,3,4-tetrahydro-[1,4]diazepino-[6,7,1-hi]indol-7-yl)pyrrole-2,5-diones as highly selective and potent inhibitors of glycogen synthase kinase-3.
Engler TA; Henry JR; Malhotra S; Cunningham B; Furness K; Brozinick J; Burkholder TP; Clay MP; Clayton J; Diefenbacher C; Hawkins E; Iversen PW; Li Y; Lindstrom TD; Marquart AL; McLean J; Mendel D; Misener E; Briere D; O'Toole JC; Porter WJ; Queener S; Reel JK; Owens RA; Brier RA; Eessalu TE; Wagner JR; Campbell RM; Vaughn R
J Med Chem; 2004 Jul; 47(16):3934-7. PubMed ID: 15267232
[TBL] [Abstract][Full Text] [Related]
16. A review of Glycogen Synthase Kinase-3 (GSK3) inhibitors for cancers therapies.
Thapa R; Gupta G; Bhat AA; Almalki WH; Alzarea SI; Kazmi I; Saleem S; Khan R; Altwaijry N; Dureja H; Singh SK; Dua K
Int J Biol Macromol; 2023 Dec; 253(Pt 7):127375. PubMed ID: 37839597
[TBL] [Abstract][Full Text] [Related]
17. Anti-diabetic efficacy of KICG1338, a novel glycogen synthase kinase-3β inhibitor, and its molecular characterization in animal models of type 2 diabetes and insulin resistance.
Kim KM; Lee KS; Lee GY; Jin H; Durrance ES; Park HS; Choi SH; Park KS; Kim YB; Jang HC; Lim S
Mol Cell Endocrinol; 2015 Jul; 409():1-10. PubMed ID: 25802191
[TBL] [Abstract][Full Text] [Related]
18. Glycogen synthase kinase-3 as drug target: from wallflower to center of attention.
Van Wauwe J; Haefner B
Drug News Perspect; 2003 Nov; 16(9):557-65. PubMed ID: 14702136
[TBL] [Abstract][Full Text] [Related]
19. Glycogen synthase kinase 3: a drug target for CNS therapies.
Bhat RV; Budd Haeberlein SL; Avila J
J Neurochem; 2004 Jun; 89(6):1313-7. PubMed ID: 15189333
[TBL] [Abstract][Full Text] [Related]
20. Glycogen synthase kinase 3 (GSK3) in the heart: a point of integration in hypertrophic signalling and a therapeutic target? A critical analysis.
Sugden PH; Fuller SJ; Weiss SC; Clerk A
Br J Pharmacol; 2008 Mar; 153 Suppl 1(Suppl 1):S137-53. PubMed ID: 18204489
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
